Biovian, a leading biopharmaceutical CDMO from Finland, uncovers the stonemasonry work of its new manufacturing facility, GeneCity.
Located in a growing technology hub at Turku, Kupittaa, the state-of-the-art facility houses a blend of cutting-edge equipment and technology. The new GeneCity facility, encompassing a total of 6,400 sqm (69,000 sqft), will support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products), such as adenoviral and AAV (adeno-associated viral) therapies along with our current manufacturing facilities. The expansion project is expected to be completed in December 2024, with the new facility fully operational by 2025.
Pirkko Kortteinen, COO and co-founder of Biovian expressed her enthusiasm about this important milestone: “This is an exciting milestone for the company and thus also for our employees. The stonemasonry work and the embedded time capsule signify the personal touch of turning science-based innovations into medicines. This project holds great significance for our team in bringing our services to the world of biotechnology”.
To add a unique touch to this milestone, Biovian has embedded a time capsule within the stonemasonry. This time capsule will reflect Biovian’s 20th anniversary year and preserve a mosaic poster with photos of our employees, 6 empty injection vials, a filling needle, which is an important part of manufacturing equipment and a template of an analysis request document, creating a bridge between Biovian people, manufacturing practices, and future generations.
Many thanks to all participants!
Special thanks to local players, Turun Teknologiakiinteistöt, Sigge Arkkitehdit, Lundén, and Elomatic Solutions Oy for your precious input in this expansion project.
Biovian Unveils the Stonemasonry Work at GeneCity FacilityDownload